BRPI1009121A2 - formulações resistentes a abuso - Google Patents

formulações resistentes a abuso

Info

Publication number
BRPI1009121A2
BRPI1009121A2 BRPI1009121A BRPI1009121A BRPI1009121A2 BR PI1009121 A2 BRPI1009121 A2 BR PI1009121A2 BR PI1009121 A BRPI1009121 A BR PI1009121A BR PI1009121 A BRPI1009121 A BR PI1009121A BR PI1009121 A2 BRPI1009121 A2 BR PI1009121A2
Authority
BR
Brazil
Prior art keywords
abuse resistant
resistant formulations
formulations
abuse
resistant
Prior art date
Application number
BRPI1009121A
Other languages
English (en)
Inventor
Sägström Anders
Dahlgren Anna
Engqvist Hakan
Bredenberg Susanne
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of BRPI1009121A2 publication Critical patent/BRPI1009121A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1009121A 2009-03-04 2010-03-02 formulações resistentes a abuso BRPI1009121A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2009000592 2009-03-04
PCT/GB2010/000374 WO2010100414A1 (en) 2009-03-04 2010-03-02 Abuse resistant formulation

Publications (1)

Publication Number Publication Date
BRPI1009121A2 true BRPI1009121A2 (pt) 2018-06-19

Family

ID=40823586

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009121A BRPI1009121A2 (pt) 2009-03-04 2010-03-02 formulações resistentes a abuso

Country Status (17)

Country Link
US (2) US9622972B2 (pt)
EP (1) EP2403482B1 (pt)
JP (1) JP5728705B2 (pt)
KR (1) KR101751906B1 (pt)
CN (1) CN102341096B (pt)
AU (1) AU2010219449B2 (pt)
BR (1) BRPI1009121A2 (pt)
CA (1) CA2753664C (pt)
DK (1) DK2403482T3 (pt)
EA (1) EA031154B1 (pt)
ES (1) ES2660674T3 (pt)
IL (1) IL214583A (pt)
MX (1) MX336355B (pt)
NO (1) NO2403482T3 (pt)
NZ (1) NZ594513A (pt)
PL (1) PL2403482T3 (pt)
WO (1) WO2010100414A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
MY150626A (en) 2009-10-30 2014-02-07 Ix Biopharma Ltd Fast dissolving solid dosage form
CN107595793B (zh) * 2012-11-30 2020-11-13 阿库拉制药公司 活性药物成分的自调节释放
US10420729B2 (en) * 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
GB201502073D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
WO2016140961A1 (en) 2015-03-02 2016-09-09 Mc10, Inc. Perspiration sensor
EP3210596A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
KR20180128917A (ko) * 2016-02-29 2018-12-04 엠플리큐어 아베 니코틴의 증발 및 흡입용 장치
CN105997907A (zh) * 2016-05-16 2016-10-12 胡小丽 高血压治疗药丸
CN105997915A (zh) * 2016-05-16 2016-10-12 张阳 一种高血压治疗用缓释片剂
CN105769798A (zh) * 2016-05-16 2016-07-20 张阳 一种高血压治疗药物的制备方法
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
GB201714412D0 (en) * 2017-09-07 2017-10-25 Emplicure Ab Evaporation devices containing plant material
CN108720990A (zh) * 2018-06-04 2018-11-02 界首市龙鑫生物科技有限公司 一种能够加快伤口愈合的医用冷敷贴
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2023187225A1 (en) * 2022-04-01 2023-10-05 Amplicon Ab Alkaline intraoral products

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0391893B1 (en) 1983-11-14 1993-08-25 The University of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
GB2196252B (en) 1986-09-18 1990-10-17 London Pharmacy Innovation Gastric controlled-release dosage forms
IT1197316B (it) 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
JP2702953B2 (ja) 1988-01-30 1998-01-26 オリンパス光学工業株式会社 薬液含浸セラミックス
IT1216570B (it) 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
JPH0230988A (ja) 1988-07-20 1990-02-01 Toshiba Corp 宇宙軌道上発電プラント
JPH02268104A (ja) 1989-04-07 1990-11-01 Kanebo Ltd 抗菌性組成物
US5443812A (en) 1989-04-24 1995-08-22 Kanebo Ltd. Stabilized synthetic zeolite and a process for the preparation thereof
JPH07188000A (ja) 1993-12-27 1995-07-25 Bridgestone Corp 薬用被覆材
JPH0930988A (ja) 1995-07-21 1997-02-04 Sumitomo Osaka Cement Co Ltd 薬剤徐放性多孔質セラミックス成形体及びその製造方法
GB2307862A (en) 1995-12-05 1997-06-11 David Jehan Patch structures for transdermal therapy
WO1998023556A1 (fr) 1996-11-25 1998-06-04 Kabushiki Kaisya Advance Procede de production de ceramiques
US5902591A (en) 1997-04-03 1999-05-11 La Prairie Sa Stable topical cosmetic/pharmaceutical emulsion compositions containing ascorbic acid
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6123925A (en) 1998-07-27 2000-09-26 Healthshield Technologies L.L.C. Antibiotic toothpaste
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
AUPQ573300A0 (en) 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
EP1272440A2 (en) 2000-03-24 2003-01-08 Mark B. Lyles High density porous materials
AU2001246883B2 (en) 2000-04-11 2004-08-12 Sankyo Company, Limited Stabilized pharmaceutical compositions containing calcium channel blockers
US20020122828A1 (en) 2001-03-02 2002-09-05 Jun Liu Hybrid porous materials for controlled release
US6767557B2 (en) * 2001-03-05 2004-07-27 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
WO2003035135A1 (en) 2001-09-24 2003-05-01 Boston Scientific Limited Optimized dosing for drug coated stents
ES2398910T3 (es) 2001-09-28 2013-03-22 Tntgamble, Inc. Sistema de aporte para componentes biológicos
JP2005518354A (ja) 2001-11-19 2005-06-23 コントロール・デリバリー・システムズ・インコーポレイテッド コドラッグを含有する医薬組成物
ES2361068T3 (es) 2002-04-23 2011-06-13 Durect Corporation Sistemas analgésicos transdérmicos con potencial de abuso reducido.
WO2003092785A1 (en) 2002-04-30 2003-11-13 Morteza Shirkhanzadeh Arrays of microneedles comprising porous calcium phosphate coating and bioactive agents
US8062573B2 (en) 2002-09-16 2011-11-22 Theraject, Inc. Solid micro-perforators and methods of use
SE524334C2 (sv) 2002-09-30 2004-07-27 Cerbio Tech Ab Värmegenererande biokompatibla keramiska material och förfarande för dess framställning
SE525236C2 (sv) 2002-10-31 2005-01-11 Cerbio Tech Ab Förfarande för framställning av strukturerade keramiska beläggningar och belagda anordningar framställda med detta förfarande
SE524494C2 (sv) 2002-12-31 2004-08-17 Doxa Ab Kemiskt bundna biomaterialelement med skräddarsydda egenskaper
EP1674094A4 (en) 2003-10-15 2009-12-09 Nanoegg Res Lab Inc COMPOSITION CONTAINING RETINOIC ACID NANOPARTICLES COATED WITH A VERSATILE METAL INORGANIC SALT
KR20060115398A (ko) 2003-10-29 2006-11-08 독사 악티에볼락 개선된 생체 재료의 초기 및 최종 특성을 위한 2단계시스템
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
KR101184138B1 (ko) 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
JP4832082B2 (ja) 2004-02-03 2011-12-07 久光製薬株式会社 経皮薬物投与装置用インタフェース
US7315758B2 (en) 2004-06-03 2008-01-01 Lynntech, Inc. Transdermal delivery of therapeutic agent
US20060016578A1 (en) * 2004-06-24 2006-01-26 Shine Ying Co., Ltd. [high-performance two-phase flow evaporator]
CN101001613B (zh) 2004-06-28 2010-09-29 生命周期药物公司 作为液体制剂载体的多孔片剂
US20060127486A1 (en) 2004-07-13 2006-06-15 Moerck Rudi E Ceramic structures for prevention of drug diversion
AU2005271782A1 (en) * 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for controlled release of drugs
WO2006015299A2 (en) 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
CA2577583A1 (en) 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US8535702B2 (en) 2005-02-01 2013-09-17 Boston Scientific Scimed, Inc. Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
CA2599951A1 (en) 2005-03-04 2006-09-14 Altairnano, Inc. Ceramic structures for controlled release of biologically active substances
DE102005040429A1 (de) 2005-08-25 2007-03-01 Heraeus Kulzer Gmbh Wirkstofffreisetzungssystem und seine Verwendung
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US7682445B2 (en) 2005-12-08 2010-03-23 Doxa Ab Powdered CBC system with improved reaction feature
WO2007074349A2 (en) 2005-12-29 2007-07-05 Robert Basic Mineral-herbal preparation consisting of zeolite and astragalus membranaceus root extract to treat allergies
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20070248656A1 (en) 2006-04-25 2007-10-25 Galer Bradley S Topical preparation dispensers and methods of using the same
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
DE102006028781A1 (de) 2006-06-23 2007-12-27 Robert Bosch Gmbh Verfahren zur Herstellung von porösen Mikronadeln und ihre Verwendung
US20080214987A1 (en) 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
US8778377B2 (en) 2007-03-01 2014-07-15 Doxa Ab Drug implant carrier for drug delivery
WO2008105737A1 (en) 2007-03-01 2008-09-04 Doxa Ab Stable cement composition for orthopaedic and dental use
WO2008105738A1 (en) 2007-03-01 2008-09-04 Doxa Ab Injectable cement composition for orthopaedic and dental use
US20090061003A1 (en) 2007-03-28 2009-03-05 Doxa Ab Carriers for drug delivery
CN101104080B (zh) 2007-04-24 2011-06-22 深圳市鸿华投资有限公司 沸石止血敷料及其制备方法和用途
GB0709541D0 (en) 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
EP2100850A1 (en) 2008-03-11 2009-09-16 Stichting Voor De Technische Wetenschappen Microneedle array and a method for manufacturing microneedles
WO2010096704A2 (en) 2009-02-19 2010-08-26 Alex Garfield Bonner Porous interpenetrating polymer network

Also Published As

Publication number Publication date
AU2010219449A1 (en) 2011-09-01
US9622972B2 (en) 2017-04-18
NO2403482T3 (pt) 2018-05-26
US20170239229A1 (en) 2017-08-24
EA201101281A1 (ru) 2012-02-28
US20120015007A1 (en) 2012-01-19
CN102341096A (zh) 2012-02-01
KR20110122838A (ko) 2011-11-11
IL214583A0 (en) 2011-09-27
ES2660674T3 (es) 2018-03-23
KR101751906B1 (ko) 2017-06-29
JP2012519675A (ja) 2012-08-30
JP5728705B2 (ja) 2015-06-03
MX2011009214A (es) 2011-09-28
IL214583A (en) 2016-04-21
WO2010100414A1 (en) 2010-09-10
AU2010219449B2 (en) 2014-12-18
CN102341096B (zh) 2015-02-18
CA2753664A1 (en) 2010-09-10
DK2403482T3 (en) 2018-03-05
EP2403482A1 (en) 2012-01-11
EA031154B1 (ru) 2018-11-30
EP2403482B1 (en) 2017-12-27
CA2753664C (en) 2019-11-05
PL2403482T3 (pl) 2018-06-29
MX336355B (es) 2016-01-14
NZ594513A (en) 2013-10-25
US10543203B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
BRPI1009121A2 (pt) formulações resistentes a abuso
IT1393131B1 (it) Controvento a ingobbamento limitato
DK2289304T3 (da) Høstmaskine
IL221409A (en) Resistant formulations for abuse
DK2225988T3 (da) Dispenserhus
FR2952790B1 (fr) Chaussure a semelage ameliore
GB0912034D0 (en) Patterning
DK3320979T3 (da) Dispenser
DK2429882T3 (da) Forbindelsesanordning
ES1067502Y (es) Columbario modular
BR112013008850A2 (pt) artigos resistentes a manchas
BRPI1012729A2 (pt) dispensador
IT1398233B1 (it) Tostapane
IT1397007B1 (it) Dispenser
BR112012006693A2 (pt) combinação
FR2946241B1 (fr) Zesteur a savon
IT1396671B1 (it) Scambiatore a microcanali
BRPI1013568A2 (pt) um queimador
BR112012006968A2 (pt) combinação
ES1070838Y (es) Pavimento modular
FI20090342A0 (fi) Henkilökuljetin
IT1397375B1 (it) Cassero a disarmo rapido
GB2472581B (en) A puzzle
IT1396677B1 (it) Gioco
ES1072838Y (es) Posavaso

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements